Shockwave Receives FDA Breakthrough Device Designation for the Investigational Coronary IVL System
IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
42 patients, 42 valves safely implanted through calcified #iliofemoral access! Learn more about #IVL -Facilitated T… https://t.co/NyiImIezmQ
We were thrilled to launch #ShockwaveIVL in Israel during the very successful #ICI2019 meeting in Tel Aviv this wee… https://t.co/JqhIr2vmVt
First @ShockwaveIVL cases in Israel! Congratulations Dr. Yaron Almagor & Dr. Rami Jubeh from Shaarei Zedek Hospital… https://t.co/7qHXyVMpas
Beautiful #ShockwaveIVL assisted #TAVI procedure by Dr. Vlasis Ninios! Successful preparation with a 6mm… https://t.co/3Iq87gnOSy
Hot off the press! We’re honored to be featured in Singapore’s most widely read paper, Straits Times! Dr. Tan Chong… https://t.co/Zs3JDTb7RF
Learn more about #IntravascularLithotripsy -Enabled Vascular Access for Transfemoral #TAVR Procedures in the… https://t.co/CJH74ggy34
Congratulations Drs. Christos Christou, Savvas Constantinides, & Stefan Harb on performing the 1st #ShockwaveIVL pr… https://t.co/3xsVtobpns
How well do you know the newest #ShockwaveIVL catheter? Check out the #ShockwaveS4 page to learn more about the tec… https://t.co/dWkdbnNqEk
For those in the EU interested in coronary #IVL, read about the #DISRUPTCAD2 clinical results in the @CircIntv publ… https://t.co/UjbqjuRH6C
Outstanding work fighting #PAD and saving limbs in the boot capital of the world! Beautiful 1st #ShockwaveIVL case… https://t.co/PjXUHi1spy
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
